Clinical Research Directory

Inclusion Criteria: * Patients aged 20 to 70 years * Women diagnosed with primary invasive breast cancer through biopsy * Patients with clinically and imaging-suspected axillary lymph node metastasis, confirmed pathologically (aspiration cytology or needle biopsy) * Clinically staged T1-T4, N1-3 * Patients who have fully understood the clinical trial content (if possible) and signed the informed consent form Exclusion Criteria: * Patients with inadequate radiological evaluation of the axilla before surgery * Recurrent breast cancer or inflammatory breast cancer * Breast cancer with distant metastasis (Stage 4) * Patients with a history of hypersensitivity to the components of the investigational drug * Patients scheduled for axillary dissection that does not require targeting of the target lesion * Patients with active connective tissue disease (e.g., scleroderma, lupus) that has invaded the skin * Patients with locally advanced breast cancer or inflammatory locally advanced breast cancer that is not amenable to surgery * Patients with a history of hypersensitivity to the main component or excipients of the investigational drug * Female subjects who may become pregnant during the clinical trial period and do not agree to use a highly effective non-hormonal contraception method (e.g., sterilization, intrauterine device, complete abstinence, vasectomy partner) from the time of investigational drug injection until the follow-up visit * Pregnant or lactating women * Patients who have participated in another clinical trial within 12 weeks before enrollment in this clinical trial * Patients deemed unsuitable for participation by the investigator for any other reason